PACILIO, MASSIMILIANO
 Distribuzione geografica
Continente #
NA - Nord America 485
EU - Europa 250
AS - Asia 79
AF - Africa 2
OC - Oceania 1
SA - Sud America 1
Totale 818
Nazione #
US - Stati Uniti d'America 474
IT - Italia 122
SE - Svezia 39
IN - India 36
CN - Cina 30
DE - Germania 28
IE - Irlanda 19
AT - Austria 10
CA - Canada 10
SG - Singapore 10
FI - Finlandia 8
BG - Bulgaria 6
GB - Regno Unito 4
CH - Svizzera 3
RO - Romania 3
JP - Giappone 2
PL - Polonia 2
TG - Togo 2
AR - Argentina 1
AU - Australia 1
BE - Belgio 1
FR - Francia 1
KR - Corea 1
MX - Messico 1
NL - Olanda 1
NO - Norvegia 1
RU - Federazione Russa 1
UA - Ucraina 1
Totale 818
Città #
Rome 61
Chandler 56
Fairfield 48
Wilmington 32
Ashburn 30
Houston 26
Dearborn 24
Princeton 23
Bremen 20
Dublin 19
Seattle 17
Beijing 16
Boston 15
Lawrence 14
Cambridge 12
New York 12
Woodbridge 12
Plano 11
San Diego 10
Vienna 10
Helsinki 8
Milan 8
Andover 7
Millbury 7
Ann Arbor 6
San Paolo di Civitate 6
Sofia 6
Toronto 6
Genoa 4
Cologne 3
Naples 3
Ottawa 3
San Mateo 3
Southend 3
Agrigento 2
Dallas 2
Fiano Romano 2
Fremont 2
Harbin 2
Hebei 2
Lomé 2
Redmond 2
Redwood City 2
Verona 2
Wuhan 2
Adelaide 1
Arezzo 1
Atlanta 1
Baotou 1
Boardman 1
Bologna 1
Brussels 1
Bühl 1
Cergy 1
Chengdu 1
Des Moines 1
Falls Church 1
Federal 1
Fuzhou 1
Geneva 1
Gurugram 1
Hefei 1
L'aquila 1
Lancaster 1
Laurel 1
Lausanne 1
Lishui 1
Mexico City 1
Minoh 1
Montréal 1
Munich 1
Nanjing 1
Nashville 1
Norwalk 1
Novara 1
Oslo 1
Phoenix 1
Piacenza 1
Pisa 1
Pistoia 1
Renens 1
Sacramento 1
San Giorgio A Cremano 1
Sestu 1
Seversk 1
Shenyang 1
Stockholm 1
Taranto 1
Trumbull 1
Warsaw 1
Totale 608
Nome #
Immunoscintigraphy for therapy decision making and follow-up of biological therapies 74
Deep seated tumour treatments with electrons of high energy delivered at FLASH rates: the example of prostate cancer 68
Psychological status and pain outcome evaluation in patients with painful bone metastases from castration resistant prostate cancer treated with 223Radium. 62
A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with223Radium-dichloride 53
123I-mibg Imaging For Parkinson’S Disease: The Diagnostic Value Of The Early Heart-to-mediastinum Count Ratio 51
Myocardial blood flow estimates from dynamic contrast-enhanced magnetic resonance imaging: three quantitative methods 49
Diagnostic value of the early heart-to-mediastinum count ratio in cardiac 123I-mIBG imaging for Parkinson's disease 49
Dose-response correlation in radioiodine therapy of hyperthyroidism from nodular thyroid disease 44
Technical note: a wearable radiation measurement system for collection of patient-specific time-activity data in radiopharmaceutical therapy: system design and Monte Carlo simulation results 40
Analysis of Clinical parameters for the outcame prediction of mCRPC patients treated with Ra-223-dichloride 36
Role of tALP and ECOG Performance Status in predicting survival in mCRPC patients receiving 223Ra-dichloride 35
Lesion dosimetry and follow-up for a large group of castration-resistant prostate cancer (CRPC) patients and bone metastases treated with 223Ra therapy 34
Lesions dosimetry for 223Ra therapy of bone metastases from castration-resistant prostate cancer 33
Lesion dosimetry for Ra-223 therapy of bone metastases from castration-resistant prostate cancer: patients eligibility criterion and update of dosimetric assessments 32
Definition of a Predictive Score to guide therapeutic management in metastatic CRPC patients eligible to Radium-223 31
Correlation between Bone Lesion Dosimetry and Pain Outcome in Patients (pts) with Castration-Resistant Prostate Cancer (CRPC)undergoing 223Ra-dichloride Therapy 30
I-131 differentiated thyroid cancer therapy in pediatric patients based on I-123 pre-therapeutic red marrow dosimetry 29
Feasibility of 223 Ra imaging for clinical purpose 28
Feasibility of 223Ra quantitative imaging for lesion dosimetry 26
Role of psychological status related to pain outcome and bone lesion dosimetry in patients with bone metastatic Castration-Resistant Prostate Cancer (mCRPC) treated with 223Radium 26
Treatment planning of intracranial lesions with {VHEE}: comparing conventional and {FLASH} irradiation potential with state-of-the-art photon and proton radiotherapy 21
Personalized dosimetry in the context of radioiodine therapy for differentiated thyroid cancer 19
Yttrium-90 radioembolization of colorectal cancer liver metastases: a systematic review of clinical evidence 19
Dosimetric principles of targeted radiotherapy and radioimmunotherapy 4
Experimental validation of an innovative approach in biokinetics study for personalised dosimetry of molecular radiation therapy treatments 3
Totale 896
Categoria #
all - tutte 2.901
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.901


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201921 0 0 0 0 0 0 0 0 0 14 4 3
2019/2020155 11 0 2 2 9 31 43 17 20 11 8 1
2020/202162 9 2 4 6 0 10 4 2 5 13 7 0
2021/2022196 0 8 10 8 24 13 12 18 17 11 38 37
2022/2023269 48 37 19 54 23 21 7 12 29 0 14 5
2023/2024166 12 19 13 12 17 28 7 35 8 15 0 0
Totale 896